Xilio Therapeutics (XLO) Expected to Announce Earnings on Thursday

Posted by on May 12th, 2026

Xilio Therapeutics (NASDAQ:XLO – Get Free Report) is expected to post its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect Xilio Therapeutics to post earnings of ($0.66) per share and revenue of $8.52 million for the quarter. Individuals can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Thursday, May 21, 2026 at 9:30 AM ET.

Xilio Therapeutics (NASDAQ:XLO – Get Free Report) last announced its quarterly earnings data on Monday, March 23rd. The company reported ($0.85) EPS for the quarter, beating analysts’ consensus estimates of ($1.68) by $0.83. The firm had revenue of $13.69 million during the quarter, compared to the consensus estimate of $10.90 million. Xilio Therapeutics had a negative net margin of 80.05% and a negative return on equity of 393.01%. On average, analysts expect Xilio Therapeutics to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Xilio Therapeutics Stock Down 0.1%

Shares of NASDAQ:XLO opened at $7.73 on Tuesday. The company has a market cap of $46.23 million, a P/E ratio of -1.41 and a beta of -0.16. Xilio Therapeutics has a 52 week low of $6.47 and a 52 week high of $16.52. The company has a 50-day moving average price of $8.05 and a 200 day moving average price of $9.01.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of XLO. Jane Street Group LLC purchased a new position in shares of Xilio Therapeutics during the 4th quarter worth approximately $27,000. Velan Capital Investment Management LP purchased a new position in shares of Xilio Therapeutics during the 4th quarter worth approximately $109,000. State Street Corp increased its stake in shares of Xilio Therapeutics by 13.7% during the 4th quarter. State Street Corp now owns 186,390 shares of the company’s stock worth $119,000 after purchasing an additional 22,500 shares in the last quarter. Renaissance Technologies LLC increased its stake in shares of Xilio Therapeutics by 68.3% during the 4th quarter. Renaissance Technologies LLC now owns 344,416 shares of the company’s stock worth $220,000 after purchasing an additional 139,716 shares in the last quarter. Finally, Squarepoint Ops LLC increased its stake in shares of Xilio Therapeutics by 39.6% during the 3rd quarter. Squarepoint Ops LLC now owns 328,794 shares of the company’s stock worth $277,000 after purchasing an additional 93,338 shares in the last quarter. 54.29% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have recently issued reports on XLO. Weiss Ratings upgraded shares of Xilio Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday. Wall Street Zen upgraded shares of Xilio Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, March 28th. One equities research analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $28.00.

Get Our Latest Stock Analysis on XLO

About Xilio Therapeutics

(Get Free Report)

Xilio Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of tumor‐targeted cytokine therapeutics for the treatment of cancer. The company leverages a proprietary platform to design pro‐drug versions of potent immune‐modulating cytokines, enabling local activation of immune responses within the tumor microenvironment while limiting systemic exposure and toxicity.

The company’s lead programs utilize engineered interleukin‐12 (IL‐12) and interleukin‐2 (IL‐2) molecules fused to tumor‐binding antibodies or peptide ligands.

Featured Articles

Earnings History for Xilio Therapeutics (NASDAQ:XLO)

Receive News & Ratings for Xilio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xilio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.